Objective: To evaluate the postoperative outcome of multiple slit on plaque plication technique for the treatment of Peyronie Je Jong Ki. Methods: We retrospectively evaluated 22 patients who underwent plaque incision with penile plication for surgical treatment of Peyronieu Geon Moon of tamoxifen, L-l treatment between 2009 and 2014. Patients were grouped by pre-operative degree of penile curvature such as Group I: mild [n=5 (22%)], Group II: moderate [n=11 (50%)], and Group III: severe [n=6 (27%)]. On the thorough review of medical records, we evaluated (I) correction of the curvature; (II) sexual function; and (III) any penile shortening or other complications. Results: The mean postoperative follow-up period was 39 months. Complete correction of the curvature was obtained in 21 patients (95%). As inevitable complication, minimal penile shortening (<1.5 cm) was reported by 14 patients (82%) but did not adversely affect sexual intercourse (0%) and all patients accepted for penile shortening. And 19 patients had good erectile function [International Index of Erectile Function (IIEF)5 >21]. The most frequent complication was the subcutaneous penile edema in three patients (13.6%), which was resolved within about 3 months after surgery. Conclusions: As modified technique, multiple slit on plaque with plication is a simple, non-invasive and effective technique for correcting penile curvature regardless of curvature severity. And the degree of penile curvature does not significantly predict the amount of penile length loss.
Objectives:
Recently, tadalafil was found to be effective for treating lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Testosterone (T) regulates nitric oxide synthase and is necessary to achieve an optimum response to PDE5 inhibitors. In the present study, we determined whether T replacement in men with low T levels receiving tadalafil to treat LUTS improved the response of tadalafil on LUTS. Methods: The present 12-week study was a randomized parallel study of clinical outcomes in men aged ≥40 years with symptomatic BPH (IPSS ≥12), prostate volumes ≥30 mL, and testosterone levels less than 300 ng/dl. Eligible patients received a combination of tadalafil 5 mg once daily and placement of a transdermal gel containing 10 g T (n=44), or tadalafil alone (n=46). The primary outcomes were posttreatment IPSS, peak urinary flow rate, and post-void residual urine volume (PVR). Secondary outcomes were changes in IIEF-EF domain scores, Global Assessment Questionnaire (GAQ) scores, and Life Satisfaction
